Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers

Kariagina A. , Aupperlee M.D. , Haslam S.Z. . Progesterone receptor isoform functions in normal breast development and breast cancer. Crit Rev Eukaryot Gene Expr 2008; 18: 11–33.

Gizard F. , Robillard R. , Gross B. . TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol 2006; 26: 7632–44.

Kastner P. , Krust A. , Turcotte B. . Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990; 9: 1603–14.

Hopp T.A. , Weiss H.L. , Hilsenbeck S.G. . Breast cancer patients with progesterone receptor PR-A-Rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004; 10: 2751–60.

Vegeto E. , Shabaz M.M. , Wen D.X. . Human progesterone receptor A form is a cell- and promoterspecific repressor of human progesterone receptor B function. Mol Endocrinol 1993; 7: 1244–55.

Mote P.A. , Bartow S. , Tran N. , Clarke C.L. . Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 2002; 72: 163–72.

Wright C. , Angus B. , Nicholson S. . Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087–90.

Arpino G. , Wiechmann L. , Osborne C.K. , Schiff R. . Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29: 217–33.

Pawlowski V. , Révillion F. , Hebbar M. , Hornez L. , Peyrat J.P. . Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 5: 4217–25.

Révillion F. , Lhotellier V. , Hornez L. , Bonneterre J. , Peyrat J.P. . ErbB/HER ligands in human breast cancer and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008; 19: 73–80.

Peyrat J.P. , Bonneterre J. , Beuscart R. , Djiane J. , Demaille A. . Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 1988; 48: 6429–33.

Koenders T. , and Benraad T.J. . Quality control of estrogen receptor assays in The Netherlands. Breast Cancer Res Treat 1983; 3: 255–66.

De Cremoux P. , Tran-Perennou C. , Elie C. . Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol 2002; 64: 507–15.

Applied Biosystems, User bulletin # 2. Relative quantification of gene expression, 1997.

Osborne C.K. . Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998; 51: 227–38.

Arpino G. , Green S.J. , Alfred D.C. . HER2-amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer, a southwest oncology group study. Clin Cancer Res 2004; 10: 5670–76.

Gago F.E. , Fanelli M.A. , Ciocca D.R. . Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mol Biol 2006; 98: 36–40.

Gee J.MW , Harper M.E. , Hutcheson I.R. . The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) Improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003; 144: 5105–17.

Gutteridge E. , Agrawal A. , Nicholson R. . The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. Int J Cancer 2010; 126: 1806–16.

Johnston S.R. . New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 1979–87.

Smith I.E. , Walsh G. , Skene A. . A Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007; 25: 3816–22.

Polychronis A. , Sinnett H.D. , Hadjiminas D. . Preoperative gefitinib versus gefitinib and anastrozole in post-menopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005; 6: 383–91.

Cristofanilli M. , Valero V. , Mangalik A. . Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor–positive metastatic breast cancer. Clin Cancer Res 2010; 16: 1904–14.

Kaufman B. , Mackey J.R. , Clemens M. . Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529–37.